Cook Study of Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions Exceeds 50 Percent Enrollment


February 7, 2013

February 7, 2013 — With more than 100 patients enrolled, Cook Medical has exceeded 50 percent enrollment in the Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions clinical trial. The first-of-its-kind, prospective, multicenter study is evaluating the retrograde tibiopedal vascular access technique for treating critical limb ischemia (CLI), a manifestation of peripheral arterial disease (PAD).

According to trial’s global principal investigator, Craig Walker, M.D., the founder, president and medical director of the Cardiovascular Institute of the South in Louisiana, up to 200 patients with totally occluded lower-limb arteries will be enrolled in the study. Physicians will assess the technical success rates of the new procedure both for gaining vascular access via the foot and for crossing the lesion. Patient follow-up will consist of a telephone interview approximately 30 days after the procedure.

Using the below-the-knee, retrograde tibiopedal approach, a physician gains vascular access below the knee and advances wire guides and catheters up the leg to reach and cross arterial blockages so that the blockages may be opened. Individuals and single centers have reported initial success with the technique, which is often tried after a traditional antegrade vascular approach from above the knee fails.

The trial is open at seven trial sites across the United States: Terrebonne Medical Center in Houma, La., First Coast Cardiovascular Institute in Jacksonville, Fla., Metro Heart and Vascular in Wyoming, Mich., and Rex Hospital, Inc. in Raleigh, N.C., Washington Hospital Center, D.C., West Virginia University, W.V., and Mount Sinai Medical Center, Miami, Fla. Patients also are being enrolled at several sites in the European Union.

CLI is a severe obstruction of the arteries that decreases blood flow to the extremities, producing pain and skin ulcers or sores. The condition, which affects up to 300,000 people a year in the United States, is the end stage of lower-extremity PAD and poses a significant risk of limb loss. Currently, 25 percent of CLI patients undergo amputation as a primary treatment. Within two years of treatment, 25 percent of these patients die and another 30 percent experience additional lower-limb amputation. The mortality rate at five years after amputation can be as high as 68 percent.

For more information: